Clinical Trials Search
Clinical Trial 19112
Interventions:BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Study Type: Treatment
Phase of Study: Phase I
- Jonathan Strosberg
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Primary Objective: a.) To evaluate the RECIST 1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. Secondary Objectives: a.) To evaluate toxicities in each cohort. b.) To estimate overall survival (OS), progression-free survival (PFS), clinical benefit rate; and to estimate immune-related ORR (irORR), and immune-related PFS (irPFS) by unidimensional immune-related response criteria. c.) To collect specimens for banking for use in future correlative biomarker research studies.